The U.S. cost-effectiveness watchdog ICER plans to put its number crunching to work on price hikes. With the help of some new funding, the group plans to unveil in October its first annual list of increases that aren't supported by new clinical evidence.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,